Parmacogenomics based drug design for asthma
||International Journal of Biotech Trends and Technology (IJBTT)|
|© 2013 by IJBTT Journal|
|Volume - 3 Issue - 3
|Year of Publication : 2013|
|Authors :D. Rachel Evangelene Tulip, K. Krishnadevi, K.K. Surya, K.Sekar|
D. Rachel Evangelene Tulip, K. Krishnadevi, K.K. Surya, K.Sekar "Parmacogenomics based drug design for asthma",International Journal of Biotech Trends and Technology (IJBTT), V3(3):1-30 July - September 2013. Published by Seventh Sense Research Group.
Each sub-population will respond to a particular drug in a different way based upon the genetic profile. Pharmacogenomics deals with the study of how individual’s genetic make-up plays an important role in body’s response to drugs by correlating gene expression with the drug efficacy or toxicity. Asthma is a very common chronic disease involving the respiratory system in which the airways constrict, become inflamed, and are lined with excessive amounts of mucus, often in response to one or more triggers. The ?2-adrenergic receptor is the most common adrenergic receptor in the lung, and associations between ADRB2 polymorphisms and intermediate phenotypes of asthma have been reported. The total number of SNPs in the ADRB2 gene was analyzed. According to the SNP profile, the ADRB2 protein was modeled with the help of Modeller 9V2 software. Docking studies were performed with the available candidate drugs with the help of Autodock.
1) Bach, P. B., Brown, C., Gelfand, S. E. and McCrory, D. C. (2001), “Management of acute exacerbations of chronic obstructive pulmonary disease: a summary andappraisal of published evidence”. Ann Intern Me., 134, 600-620.
2) Ballester, E., Reyes, A., Roca, J., Guitart, R., Wagner, P, D. and Rodriguez-Roisin, R. (1989), “Ventilation-perfusion mismatching in acute severe asthma:effects of salbutamol and 100% oxygen”, Thorax., 44, 258-267.
3) Barbera, J, A., Roca, J., Ferrer, A., Felez, M, A., Diaz, O, Roger, N. and Rodriguez-Roisin, R. (1997), “Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease”, Eur Respir J., 10, 1285-1291.
4) Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001;17:589-595.
5) Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE, and the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-844.
6) Bernasconi, M., Brandolese, R., Poggi, R., Manzin, E. and Rossi, A.(1990), “Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction”, Intensive Care Med., 16, 108-114.
7) Cardus, J., Burgos, F., Diaz, O., Roca, J., Barbera, J, A., Marrades, RM., Rodriguez-Roisin, R. and Wagner PD. (1997), “Increase in pulmonary ventilation-perfusion inequality with age in healthy individuals”, Am J Respir Crit Care Me., 156, 648-653.
8) Celli, B, R. and MacNee, W. (2004), “Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper”, Eur Respir J, 23., 932-946.
9) Diaz, O., Barbera, J, A., Marrades, R., Chung, K, F., Roca, J. and Rodriguez-Roisin, R. (1997), “Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation”, Am J Respir Crit Care Me., 156, 17-22.
10) Gabrijelcic, J., Casas, A., Rabinovich, R, A., Roca, J., Barbera, J,A., Chung, K, F. and Rodriguez-Roisin, R. (2004), “Formoterol protects against platelet- activating factor-induced effects in asthma”, Eur Respir J., 23, 71-75.
11) Gale, G, E., Torre-Bueno, J, R., Moon, R, E., Saltzman, H, A. and Wagner, P, D. (1985), “Ventilation-perfusion inequality in normal humans during exercise at sea level and simulated altitude”, J Appl Physio., 58, 978-988.
12) Karpel, J, P., Pesin, J., Greenberg, D. and Gentry, E. (1990), “A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD”, Chest., 98, 835-839.
13) Kessler, R., Faller, M., Fourgaut, G., Mennecier, B. and Weitzenblum, E. (1999), “Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease”, Am J Respir Care Med, 159, 158-164.
14) McDonald, D, M. (1990), “The ultrastructure and permeability of tracheobronchial blood vessels in health and disease”, Eur Respir J Suppl.,12, 572-585.
15) Mendes, E, S., Campos, M, A. and Wanner, A. (2006), “Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD”, Chest., 129, 893-898.
16) Parker, C, M., Voduc, N., Aaron, S, D., Webb, K, A. and O`Donnell, D, E. (2005), “Physiological changes during symptom recovery from moderate exacerbation of COPD”, Eur Respir J., 26, 420-428.
17) Polverino, E., Gómez, F, P., Rodríguez, A, C., Peña, A., Valera, J, L., Soler, N., Barberà, J, A., Roca, J, R. and Rodríguez-Roisin, R. (2005), “Nebulized salbutamol transiently deteriorates pulmonary gas exchange in COPD exacerbations”, Proc Am Thorac Soc, 2, 406-408.
18) Polverino, E., Gómez, F, P., Valera, J, L., Soler, N., Roca, J., Barberà, J, A. and Rodriguez- Roisin, R. (2006), “Gas exchange response to nebulized salbutamol in exacerbations and stable COPD”, Proc Am Thorac So,. 3, 721-725.
19) Rabe, K, F., Hurd, S., Anzueto, A., Barnes, P, J., Buist, S, A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R. and van Weel, C. (2006), “Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease”, Eur Respir J., 26, 480-488.
20) Ringsted, C, V., Eliasen, K., Andersen, J, B., Heslet, L. and Qvist, J. (1989), “Ventilationperfusion distributions and central hemodynamics in chronic obstructive pulmonary disease:effects of terbutaline administration”, Chest., 96, 976-983.
The application of pharmacogenomics approach to Asthma will be essential for understanding the preventive mechanisms and could lead to individualized drug therapies in future.